PTLF (Petlife Pharmaceuticals) EBITDA per Share: $-0.05 (TTM As of Feb. 2018)


What is Petlife Pharmaceuticals EBITDA per Share?

Petlife Pharmaceuticals PTLF EBITDA per Share is $-0.05 as of Feb. 2018.

Petlife Pharmaceuticals's EBITDA per Share for the three months ended in Feb. 2018 was $-0.01. Its EBITDA per Share for the trailing twelve months (TTM) ended in Feb. 2018 was $-0.05.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Petlife Pharmaceuticals's EBITDA per Share or its related term are showing as below:

PTLF's 3-Year EBITDA Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 8.9
* Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.

Petlife Pharmaceuticals's EBITDA for the three months ended in Feb. 2018 was $-0.38 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.


Petlife Pharmaceuticals  (OTCPK:PTLF) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Petlife Pharmaceuticals EBITDA per Share Related Terms


Petlife Pharmaceuticals EBITDA per Share Historical Data

* Premium members only.

The historical data trend for Petlife Pharmaceuticals's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Petlife Pharmaceuticals EBITDA per Share Chart

Petlife Pharmaceuticals Annual Data
Trend Aug08 Aug09 Aug10 Aug11 Aug12 Aug13 Aug14 Aug15 Aug16 Aug17
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.87 -0.19 -0.17 -0.40 -0.33

Petlife Pharmaceuticals Quarterly Data
May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.01 -0.02 -0.01 -0.01

Petlife Pharmaceuticals EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Petlife Pharmaceuticals's EBITDA per Share for the fiscal year that ended in Aug. 2017 is calculated as

EBITDA per Share(A: Aug. 2017 )
=EBITDA/Shares Outstanding (Diluted Average)
=-22.873/68.805
=-0.33

Petlife Pharmaceuticals's EBITDA per Share for the quarter that ended in Feb. 2018 is calculated as

EBITDA per Share(Q: Feb. 2018 )
=EBITDA/Shares Outstanding (Diluted Average)
=-0.383/74.455
=-0.01

EBITDA per Share for the trailing twelve months (TTM) ended in Feb. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of $-0.05 mean?
Petlife Pharmaceuticals (PTLF) has a EBITDA per Share of $-0.05 as of Feb. 2018. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Petlife Pharmaceuticals and its competitors.
Is Petlife Pharmaceuticals' EBITDA per Share too high?
Petlife Pharmaceuticals' current EBITDA per Share is $-0.05.
How does Petlife Pharmaceuticals' EBITDA per Share compare to PCYN and YBAO?
Petlife Pharmaceuticals' EBITDA per Share of $-0.05 can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA per Share is 8.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Drug Manufacturers company?
The median EBITDA per Share among Drug Manufacturers companies is 8.90, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Petlife Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA per Share is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Petlife Pharmaceuticals's current EBITDA per Share is $-0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petlife Pharmaceuticals stock overvalued right now?
Petlife Pharmaceuticals (PTLF) has a current EBITDA per Share of $-0.05. The current EBITDA per Share is $-0.05. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For Petlife Pharmaceuticals (PTLF), the current EBITDA per Share is $-0.05 as of Feb. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Petlife Pharmaceuticals Business Description

Address 38 West Main Street, 6th Floor, Hancock, MD, USA, 21750
Petlife Pharmaceuticals Inc specializes in the research, development, sales, and support of advanced drugs and nutraceuticals for pet cancer and autoimmune related diseases such as arthritis. It develops potentiated veterinary cancer medications and nutraceuticals, under its tradename Vitalzul based on Escozine formula. The Vitalzul is a polarized, bioactive peptide extracted from the Blue Caribbean Scorpion (Rhopularus Princeps), which contains amino acids, proteins, and minerals.